Mr. Brent Zettl reports

ZYUS LIFE SCIENCES PROVIDES UPDATE ON CLINICAL TRIAL PROGRESS AND UNIT PRIVATE PLACEMENT

Zyus Life Sciences Corp. has reached a key milestone in its continuing phase 2a UTOPIA-1 (Unique Treatment of Oncology Pain in Advanced Cancer) trial, with patient enrolment reaching 25 per cent.

Clinical trial update

Zyus's phase 2a UTOPIA-1 trial evaluating safety and preliminary analgesic efficacy of Trichomylin softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain has reached 25-per-cent enrolment. Enrolment continues across three active clinical sites, with screening and dosing activities progressing as expected. Preliminary safety and efficacy results are anticipated early Q1 of 2026.

"We are pleased to have reached 25-per-cent patient enrolment, a significant step that underscores patient interest and the ongoing unmet needs of those experiencing cancer pain," said Brent Zettl, president and chief executive officer of the company. "This milestone marks meaningful progress as the UTOPIA-1 trial continues gathering the data needed to evaluate the potential clinical benefit of Trichomylin softgel capsules."

Unit private placement update

As disclosed in the company's news release dated Nov. 7, 2025, Zyus raised a total of $1,250,000.50 in gross proceeds via a non-brokered private placement, all of which was raised in the first tranche that closed on Nov. 7, 2025. The company does not expect to close a further tranche of the private placement. However, the company continues to evaluate additional financing opportunities as needed and will provide further updates as required under applicable securities laws and TSX Venture Exchange policies.

About Zyus Life Sciences Corp.

Zyus is a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid pharmaceutical drug candidates for pain management. Currently, Zyus is conducting a phase 2a clinical trial for its lead drug candidate, Trichomylin softgel capsules. Through rigorous scientific exploration and clinical research, Zyus aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. Zyus's unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions, in pursuit of transformational impact on patients' lives.

We seek Safe Harbor.